Clinical Trial: Phase 1 Clinical Study of QLS5132 Monotherapy in Advanced Solid Tumors

U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT06932094) titled 'Phase 1 Clinical Study of QLS5132 Monotherapy in Advanced Solid Tumors' on April 10.

Brief Summary: The Phase 1 trial includes Phase 1a (dose-escalation) and Phase 1b (dose-expansion):

* Phase 1a: Assesses safety, tolerability, PK, and preliminary efficacy of QLS5132 in advanced solid tumors using ATD + BOIN, given IV every 3 weeks. Up to 12 subjects may be enrolled in promising dose levels.

* Phase 1b: Evaluates QLS5132's anti-tumor efficacy in specific CLDN6-positive solid tumors, including ovarian cancer, NSCLC, gastric cancer, and others. Expansion studies at 1~3 selected dose levels follow successful Phase 1a results.

Study...